Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment

CONCLUSIONS: The risk of HBV reactivation was not significantly associated with the timing of biologics administration after anti-HBV treatment. Thus, biologics may be initiated early in patients with IMID undergoing treatment for HBV.PMID:34840146 | DOI:10.5009/gnl210204

Source: Gut and Liver - November 29, 2021 Category: Gastroenterology Authors: Soo Min Ahn Jonggi Choi Byong Duk Ye Suk-Kyun Yang Ji Seon Oh Yong-Gil Kim Chang-Keun Lee Bin Yoo Sang Hyoung Park Seokchan Hong Source Type: research